Pittsburgh

Two-dose version of Johnson & Johnson shot 94% effective against COVID-19 – Pittsburgh, Pennsylvania

Pittsburgh, Pennsylvania 2021-09-21 07:00:00 –

Video above: The COVID-19 vaccine works for children aged 5 to 11 years, Pfizer says The two-dose version of Johnson & Johnson’s coronavirus vaccine provides 94% protection against symptomatic infections. Yes, the company said on Tuesday — making a double-dose regimen for J & J’s Janssen vaccine, which is comparable to a double-dose regimen for Moderna or Pfizer, according to the company. In addition, adding an additional dose to a single dose of the vaccine should further boost immunity and provide strong protection for people from infection. The company has released three details. A study examining various aspects of the Janssen vaccine, in summary, states that the vaccine provides long-term protection that can be enhanced with additional shots. -The Shot Johnson & Johnson Vaccine provides strong and long-term protection against COVID-19-related hospitalizations, “said Dr. Matamemen, Global Head of Research and Development at Janssen, in a statement. The ngle-shot vaccine produces a strong immune response and long-term immunological memory. And given the boost immunization of Johnson & Johnson’s COVID-19 vaccine, the defense against COVID-19 is even stronger. The Johnson & Johnson single-dose vaccine was granted an emergency use authorization by the US Food and Drug Administration in February. .27. According to the US Centers for Disease Control and Prevention, it is administered to approximately 14.8 million Americans. The company’s ongoing Phase 2 study of a two-dose regimen showed that two doses at 56-day intervals provided 100% protection against severe COVID. According to the company, the United States has -19% and 94% protection against moderate to severe COVID-19. Globally, double dose regimens provided 75% protection against moderate to severe COVID-19. Booster shots showed a 12-fold increase in antibody more than 6 months after the first dose. In contrast, the number of people who received the second vaccination in two months increased four-fold. Therefore, if you inoculate the booster later, the defense should be stronger, Dr. H, Head of the Israeli Dikones Virology and Vaccine Research Center, told CNN: A real-world evidence study of 390,000 people in the United States using health insurance records up to July found that the one-shot J & J vaccine was 81% effective in preventing hospitalization because it covered delta variants. Shown. The Johnson & Johnson Single Shot COVID-19 Vaccine showed 86% of participants under the age of 60 and 78% of participants over the age of 60 for COVID-19-related hospitalizations, “the company said. Said. In a study posted online in the preprint, a Janssen-led research team said, “The percentage of COVID-19 is% and the percentage of COVID-19-related hospitalizations is 81%.” In both groups than n, “In these states, the overall efficacy of the vaccine against COVID-19 was 79%, 78 between June and July, when the incidence of delta mutations was highest. Was%, “they added. Janssen tested the vaccine but was not directly involved in the three studies, but said the data should reassure those who received the Johnson & Johnson vaccine. “Ultimately, the job of vaccines is to keep you from getting sick, to prevent you from going to the hospital and to keep you alive, and all vaccines do that.” J & J Vaccine Data is J & J Was approved about two months later, lagging behind the data for the Moderna and Pfizer / BioNTech vaccines. Johnson & Johnson states that it will submit all this data to the FDA for potential consideration for adding booster doses and perhaps for consideration to approve a two-dose regimen. Janssen vaccines are made using a different technology than Moderna and Pfizer vaccines. They deliver messenger RNA or mRNA directly to the body wrapped in a compound called a lipid. The J & J vaccine is made using the common cold virus adenovirus. Adenovirus is designed to allow cells to enter, but then stop. Mr. Bharuch said there was room for a variety of approaches. “Single shots provide robust and durable protection for a considerable period of time while minimizing evidence of decline,” Bharuch said. -Vaccine administration is a reasonable option for people and countries seeking a simple and convenient vaccine that can be administered quickly, “he added. — And the longer you wait, the better. “It’s because the body initiates various immune responses, he said. Antibodies (immune system proteins that can flag intruders or attack them directly to neutralize them) accumulate rapidly, but can decline over time. The body also produces cells called B cells and T cells, which contribute to long-term protection. After some time, stimulating B cells with a boost (after reduced activity) appears to produce fresh antibodies more effectively, he said. Many countries where variants that can circumvent the protection provided by the vaccine were in circulation. Beta mutants are one example. There are so-called escape mutations that help hide from the immune response. It was widely distributed in South Africa, but in the United States it has been defeated by Delta and it seems that it cannot escape immune protection.

Video above: Pfizer says the COVID-19 vaccine works for children aged 5-11

The two-dose version of Johnson & Johnson’s coronavirus vaccine provides 94% protection against symptomatic infections, the company said Tuesday.

In addition, the company said adding booster immunity to a single vaccine should boost immunity and provide greater protection from infection.

The company released details of three studies examining various aspects of the Janssen vaccine and, in summary, said the vaccine provided long-term protection and could be enhanced with additional injections.

“Our extensive real-world evidence and Phase 3 studies confirm that single-shot Johnson & Johnson vaccines provide strong, long-term protection against COVID-19-related hospitalizations. “Dr. Matamimen, Global Head of Research and Development in Janssen, said in a statement.

“Our single-shot vaccine produces a strong immune response and long-term immunological memory, and given the booster immunity of the Johnson & Johnson COVID-19 vaccine, the defense against COVID-19 is even stronger. It will increase. “

The Johnson & Johnson single-dose vaccine was granted an emergency use authorization by the US Food and Drug Administration on February 27. According to the US Centers for Disease Control and Prevention, it is given to approximately 14.8 million Americans.

In a phase II trial of the company’s ongoing two-dose regimen, two doses at 56-day intervals provide 100% protection against severe COVID-19 in the United States, moderate to severe COVID-19. Was shown to provide 94% protection against. Globally, the double-dose regimen provided 75% protection against moderate to severe COVID-19, the company said.

In the second study, those who received booster shots more than 6 months after the first dose had a 12-fold increase in antibody, whereas those who received a second dose in 2 months had a 4-fold increase. It was shown that it was done. Therefore, if people later get boosters, protection should be stronger, Dr. Danbarouch, director of the Beth Israeli Dicones Virology and Vaccine Research Center, told CNN.

“If you wait longer and boost after 6 months, the boost may improve,” Barouch said.

Third, the company used a health insurance record up to July to survey 390,000 U.S. real-world evidence (covering delta variants) that the one-shot J & J vaccine was 81% effective in preventing hospitalization. He said he showed that there was.

“Johnson & Johnson’s single-shot COVID-19 vaccine showed 86% of participants under the age of 60 and 78% of participants over the age of 60 for COVID-19-related hospitalization. “The company said.

In a study posted online, a Janssen-led research team said, “Of the 390,517 vaccinated and 1,524,153 unvaccinated, vaccine efficacy is 79% for COVID-19 and COVID-19. 81% of the related hospitalizations were. ” With preprint..

“In states with high delta incidence, the proportion of COVID-19 observed was higher in both groups than in the national cohort,” they added.

“In these states, the overall vaccine efficacy of COVID-19 observed was 79%, 78% between June and July, when the incidence of delta mutations was highest,” they add. I did.

Baruch, who tested the vaccine in collaboration with Janssen but was not directly involved in the three studies, said the data should reassure those who received the Johnson & Johnson vaccine.

“All vaccines in the United States offer strong and lasting protection against severe illness and hospitalization,” he said.

“After all, the job of vaccines is to keep you from getting sick, to prevent you from going to the hospital, to keep you alive, and all vaccines do it.”

The J & J vaccine data lags behind the Moderna and Pfizer / BioNTech vaccine data. This is because J & J was approved about two months later. Johnson & Johnson states that it will submit all this data to the FDA for potential consideration for adding booster doses and perhaps for consideration to approve a two-dose regimen.

Janssen vaccines are made using a different technology than Moderna and Pfizer vaccines. They deliver messenger RNA or mRNA directly to the body wrapped in a compound called a lipid. The J & J vaccine is made using the common cold virus adenovirus. Adenovirus is designed to allow cells to enter, but then stop. It provides genetic instructions as such.

Mr. Bharuch said there was room for a variety of approaches.

“Single shots provide robust and durable protection for a considerable period of time, with minimal evidence of decline,” said Baruch.

“I think single-dose vaccines are a reasonable option for people and countries looking for a simple, convenient vaccine that can be given quickly,” he added.

“For better protection, you can give a second shot at any time between 2 and 8 months-and the longer you wait, the better.”

He said it was because the body initiated various immune responses. Antibodies—immune system proteins that can flag intruders or attack them directly to neutralize—accumulate rapidly, but can decline over time.

The body also produces cells called B cells and T cells, which contribute to long-term protection. Over time, when stimulating B cells with a boost (after reduced activity), the B cells appear to produce fresh antibodies more effectively, he said.

Bharuch said the J & J vaccine may appear to be less effective outside the United States, as it has been tested in many countries when mutants that can circumvent the protection provided by the vaccine are in circulation. Stated.

Beta variants are one example. There are so-called escape mutations that help hide from the immune response. It was widely distributed in South Africa, but in the United States it has been defeated by Delta and it seems that it cannot escape immune protection.

Two-dose version of Johnson & Johnson shot 94% effective against COVID-19 Source link Two-dose version of Johnson & Johnson shot 94% effective against COVID-19

Back to top button